We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
By Aisha Al-Muslim
Alexion Pharmaceuticals (ALXN) saw its revenue and earnings increase in the latest quarter as the biopharmaceutical company had growth driven by its U.S. launches of two drugs.
The Boston-based company reported Wednesday a profit for the second quarter of $459.8 million, or $2.04 a share, compared with a net loss of $457.4 million, or $2.05 a share, a year earlier.
Excluding one-time items, adjusted earnings were $2.64 a share, above the $2.34 a share analysts polled by FactSet were looking for.
Revenue rose 15% to $1.2 billion, above the consensus forecast of $1.17 billion. The growth was driven by Ultomiris, a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria, and Soliris, a prescription medicine that is used to treat adults with a disease called generalized myasthenia gravis.
For the full year, Alexion is increasing total revenue and earnings per share guidance.
The company is now guiding revenue of $4.75 billion to $4.8 billion, compared with its prior outlook of $4.68 billion to $4.75 billion. The company also now expects adjusted earnings of $9.65 to $9.85, compared with the previous guidance of $9.25 to $9.45.
Write to Aisha Al-Muslim at aisha.al-muslim@wsj.com
(END) Dow Jones Newswires
July 24, 2019 07:10 ET (11:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions